Latest Advances in Lung Cancer Research

Pre-surgical immunotherapy along with post-surgical immunotherapy significantly improved survival compared to chemotherapy alone for patients with operable non-small cell lung cancer.

The inflammation associated with lung cancer and depression may impact survival, despite treatments like immunotherapy and targeted therapies.

New report shows that many of the tumors with low PD-L1 have developed genetic strategies that avoid immunotherapies.

The researchers hope the findings of ‘ever-changing’ nature of lung cancer could help doctors to tailor treatments for individual patients.

Estimated rates of lung cancer screening with low-dose CT were extremely low among eligible patients across insurance types in 2017.

The phase 3 Pragmatica-Lung study has broader eligibility criteria than many other trials, expanding access to more patients and clinicians.

Keytruda plus chemotherapy before surgery and as single agent after improved outcomes for patients with resectable non-small cell lung cancer.

Patients with early-stage EGFR-mutated non-small cell lung cancer benefited from treatment with osimertinib, results of the phase 3 ADAURA trial showed.

Research study shows pacritinib has the ability to selectively target in squamous cell but does not impact normal glucose metabolism.

Removing only a portion of lobes is as effective as the traditional surgery for some patients with early-stage lung cancer.

New clinical trial shows improved survival rates and reduced risk of recurrence in patients taking a targeted therapy for NSCLC.

The ASCO Living Guideline for advanced non-small cell lung cancer (NSCLC) with driver alterations has gotten its first update, with data from recent studies.